We are a clinical stage global biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Our first-in-class lead asset, Plinabulin, is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitor treatment in cancer patients.
Partnerships Hengrui (via Wanchunbulin): exclusive commercialization and co-development in Greater China (mainland China, Hong Kong, Macau, Taiwan); RMB 200,000K (~$29.5M) upfront; up to RMB 700,000K (~$103.2M) regulatory milestones; up to RMB 400,000K (~$59.0M) commercial milestones; royalties on net sales with minimums
Indications
prevention of chemotherapy-induced neutropenia (CIN)(Phase 3)
2nd/3rd line non-small cell lung cancer (NSCLC)(Phase 3)
Status note Described as lead asset, a 'pipeline in a drug' in multiple cancer indications. FDA issued a Complete Response Letter in November 2021 on the NDA for plinabulin + G-CSF for prevention of CIN; company cites addressing CRL concerns as a key risk factor. TPD platform (SEED) classified as discontinued operations under a December 2024 divestiture plan.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.